{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:44:31Z","timestamp":1792172671074,"version":"4.4.0"},"reference-count":132,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1185\/030079903125001668","type":"journal-article","created":{"date-parts":[[2003,5,12]],"date-time":"2003-05-12T18:13:15Z","timestamp":1052763195000},"page":"155-168","source":"Crossref","is-referenced-by-count":117,"title":["Statin-fibrate combination therapy for hyperlipidaemia: a review"],"prefix":"10.1185","volume":"19","author":[{"given":"A. S.","family":"Wierzbicki","sequence":"first","affiliation":[{"name":"Department of Chemical Pathology, St. Thomas' Hospital, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. P.","family":"Mikhailidis","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Royal Free Hospital, Pond Street,London NW3 2QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Wray","sequence":"additional","affiliation":[{"name":"Dept of Cardiology, Conquest Hospital, St. Leonards-on-Sea, East Sussex TN37 7RD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schachter","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St. Mary's Hospital, Praed Street, London W2, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cramb","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology, Queen Elizabeth II Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. G.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aberdeen Royal Infirmary, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. B.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Department of Diabetes &amp; Metabolism, Southampton Hospital, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2008,9,22]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-74-1-1"},{"key":"e_1_2_1_4_1","doi-asserted-by":"crossref","unstructured":"Assman G Schulte H. Role of triglycerides in coronary artery disease: lessons from the prospective cardiovascular Munster Study. Am J Cardiol 1992;70:10H\u201313H","DOI":"10.1016\/0002-9149(92)91084-H"},{"key":"e_1_2_1_5_1","first-page":"303","article-title":"Triglycerides and coronary heart disease: a global perspective","volume":"7","author":"Ahmad I","year":"2000","unstructured":"Ahmad I, Miller M. Triglycerides and coronary heart disease: a global perspective. J Cardiovasc Risk 2000;7:303\u20137","journal-title":"J Cardiovasc Risk"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304293281702"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/204748730000700504"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408369891234255"},{"key":"e_1_2_1_9_1","unstructured":"Packard CJ Shepherd J. Physiology of the lipoprotein transport system: an overview of lipoprotein metabolism. In Betteridge DJ Illingworth DR Shepherd J eds. Lipoproteins in Health and Disease. London: Arnold 1999:17\u201331"},{"key":"e_1_2_1_10_1","first-page":"611","volume-title":"Lipoproteins in Health and Disease","author":"Austin MA.","year":"1999","unstructured":"Austin MA. Low-density lipoprotein subclass phenotypes, triglycerides and coronary heart disease. In Betteridge DJ, Illingworth DR, Shepherd J, eds. Lipoproteins in Health and Disease. London: Arnold, 1999:611\u201319"},{"key":"e_1_2_1_11_1","unstructured":"Hodis HN Mack WJ. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J 1998;19(Suppl. A):A40\u2013A44"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.1.69"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540110029028"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.1.1"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051366"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043798-199604000-00014"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200101050-00003"},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","unstructured":"Kreissberg RA. Diabetic dyslipidemia. Am J Cardiol 1998;82:67U\u201373U","DOI":"10.1016\/S0002-9149(98)00848-0"},{"key":"e_1_2_1_19_1","doi-asserted-by":"crossref","unstructured":"Haffner SM Lehto S Ronnemaa T Pyorala K Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339: 229\u201334","DOI":"10.1056\/NEJM199807233390404"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92118-4"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.4.387"},{"key":"e_1_2_1_22_1","first-page":"463","article-title":"Epidemiology of diabetic dyslipidaemia","volume":"3","author":"Laasko M","year":"1995","unstructured":"Laasko M. Epidemiology of diabetic dyslipidaemia. Diabetes Rev 1995;3:463\u2013524","journal-title":"Diabetes Rev"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.21.6.585"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1999.1880"},{"key":"e_1_2_1_25_1","doi-asserted-by":"crossref","unstructured":"Vega GL Grundy SM. Effects of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. Am J Cardiol 1998;81:36B\u201342B","DOI":"10.1016\/S0002-9149(98)00036-8"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000057457"},{"key":"e_1_2_1_27_1","first-page":"263","article-title":"HIV and cardiovascular risk factors.","volume":"11","author":"Oluwatoyin M","year":"2001","unstructured":"Oluwatoyin M, Falusi MD, Aberg JA. HIV and cardiovascular risk factors. AIDS Reader 2001;11:263\u20138","journal-title":"AIDS Reader"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.1.4.683"},{"key":"e_1_2_1_29_1","first-page":"69B","article-title":"Comparison of statins in hypertriglyceridaemia.","author":"Stein EA","year":"1998","unstructured":"Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridaemia. Am J Cardiol 1998;81:66B\u201369B","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01012-2"},{"key":"e_1_2_1_31_1","doi-asserted-by":"crossref","unstructured":"Frost RJ Otto C Geiss HC Schwandt P Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles low-density lipoprotein subfraction distribution and hemorheological parameters in type 2 diabetes mellitus with mixed hyperlipidemia. Am J Cardiol 2001;87: 44\u20138","DOI":"10.1016\/S0002-9149(00)01270-4"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1185\/0300799009117018"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00010-1"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703149"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2000.002"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.19.2088"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-001-0015-x"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/83348"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(00)00680-9"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00352-4"},{"key":"e_1_2_1_41_1","first-page":"357","article-title":"Pravastatin and the development of diabetes mellitus","volume":"103","author":"Freeman DM","year":"2001","unstructured":"Freeman DM, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Project. Circulation 2001;103:357\u201362","journal-title":"Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Project. Circulation"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2000.00734.x"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199834020-00003"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199834050-00006"},{"key":"e_1_2_1_45_1","first-page":"2550","article-title":"Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations","volume":"81","author":"Jeng CY","year":"1996","unstructured":"Jeng CY, Sheu WH, Fuh MM, Shieh SM, Chen YD, Reaven GM. Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. J Clin Endocrinol Metab 1996;81:2550\u20133","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80021-X"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-001-0006-y"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614841"},{"key":"e_1_2_1_49_1","doi-asserted-by":"crossref","unstructured":"Zambrana JL Velasco F Castro P Concha M Valles F Montilla P Jiminez-Pereperez JA Lopez-Miranda J Perez-Jimenez F. Comparison of bezafibrate versus lovastatin for lowering plasma insulin fibrinogen and plasminogen activator inhibitor-1 concentrations in hyperlipidemic heart transplant patients. Am J Cardiol 1997;80: 836\u201340","DOI":"10.1016\/S0002-9149(97)00532-8"},{"key":"e_1_2_1_50_1","first-page":"549","article-title":"Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, tplasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study)","volume":"83","author":"Cortellaro M","year":"2000","unstructured":"Cortellaro M, Cofrancesco E, Boschetti C, et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, tplasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment. Thromb Haemost 2000;83:549\u201353","journal-title":"Fluvastatin Alone and in Combination Treatment. Thromb Haemost"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5006"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199906000-00006"},{"key":"e_1_2_1_53_1","doi-asserted-by":"crossref","unstructured":"Ridker PM Rifai N Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103: 1191\u20133","DOI":"10.1161\/01.CIR.103.9.1191"},{"key":"e_1_2_1_54_1","first-page":"230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein.","volume":"100","author":"Ridker PM","year":"1999","unstructured":"Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230\u20135","journal-title":"The Cholesterol and Recurrent Events (CARE) Investigators. Circulation"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.21.4.481"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.9.1194"},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(01)00227-9"},{"key":"e_1_2_1_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(97)00252-9"},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01516-2"},{"key":"e_1_2_1_60_1","doi-asserted-by":"crossref","unstructured":"Wood D Durrington P Poulter N McInnes G Rees A Wray R on behalf of the Societies Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(Suppl. 2):S1\u201329","DOI":"10.1136\/hrt.80.2008.1S"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908053410604"},{"key":"e_1_2_1_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711123172001"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.7.1779"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.1.21"},{"key":"e_1_2_1_65_1","first-page":"379","article-title":"WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up","volume":"2","author":"Committee of Principal Investigators","year":"1980","unstructured":"Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1980;2:379\u201385","journal-title":"Report of the Committee of Principal Investigators. Lancet"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb01029.x"},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.4.614"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.23.2513"},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199707)14:7<513::AID-DIA427>3.0.CO;2-S"},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.16.1893"},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732050-00005"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4274(02)00010-3"},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1995.tb01530.x"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.12.1993"},{"key":"e_1_2_1_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199512000-00027"},{"key":"e_1_2_1_76_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.115542"},{"key":"e_1_2_1_77_1","doi-asserted-by":"publisher","DOI":"10.1159\/000047304"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199819050-00003"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00846.x"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022008874"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-199612000-00008"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/16.1.5"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)00022-1"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79858-5"},{"key":"e_1_2_1_85_1","first-page":"421","article-title":"Combined bezafibrate and simvastatin treatment for mixed hyperlipidemia.","volume":"88","author":"Kehely A","year":"1995","unstructured":"Kehely A, MacMahon M, Barbir M, Wray R, Hunt BJ, Prescott RJ, Thompson GR. Combined bezafibrate and simvastatin treatment for mixed hyperlipidemia. Q J Med 1995;88:421\u20137","journal-title":"Q J Med"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00430-X"},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00726-7"},{"key":"e_1_2_1_88_1","doi-asserted-by":"crossref","unstructured":"Eliav O Schurr D Pfister P Friedlander Y Leitersdorf E. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995;76A\u201379A","DOI":"10.1016\/S0002-9149(06)80017-2"},{"key":"e_1_2_1_89_1","doi-asserted-by":"crossref","unstructured":"Ellen RL McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81:60B\u201365B","DOI":"10.1016\/S0002-9149(98)00040-X"},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.74.1.14"},{"key":"e_1_2_1_91_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2000.00646.x"},{"key":"e_1_2_1_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00030-2"},{"key":"e_1_2_1_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000213"},{"key":"e_1_2_1_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(99)00013-3"},{"key":"e_1_2_1_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00379-8"},{"key":"e_1_2_1_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200003000-00003"},{"issue":"1","key":"e_1_2_1_97_1","first-page":"S64\u2013S67","article-title":"Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil","volume":"13","author":"Vergoulas G","year":"2000","unstructured":"Vergoulas G, Miserlis G, Solonaki F, et al. Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil. Transplant Int 2000;13 Suppl 1:S64\u2013S67","journal-title":"Transplant Int"},{"key":"e_1_2_1_98_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/90.10.631"},{"key":"e_1_2_1_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(99)90009-4"},{"key":"e_1_2_1_100_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.3.1042"},{"key":"e_1_2_1_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11203-7"},{"key":"e_1_2_1_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(90)90256-C"},{"key":"e_1_2_1_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)65951-X"},{"key":"e_1_2_1_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02208-1"},{"issue":"2","key":"e_1_2_1_105_1","first-page":"B49","article-title":"Lipid intervention trials in diabetes","volume":"23","author":"Steiner G","year":"2000","unstructured":"Steiner G. Lipid intervention trials in diabetes. Diabetes Care 2000;23(Suppl 2):B49\u201353","journal-title":"Diabetes Care"},{"key":"e_1_2_1_106_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200202143460721"},{"key":"e_1_2_1_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02436-0"},{"key":"e_1_2_1_108_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.5.477"},{"key":"e_1_2_1_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"e_1_2_1_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701163360301"},{"key":"e_1_2_1_111_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000165"},{"key":"e_1_2_1_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011090"},{"key":"e_1_2_1_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02258-5"},{"key":"e_1_2_1_114_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.14.1568"},{"key":"e_1_2_1_115_1","first-page":"S315","article-title":"Niacin-based therapy for dyslipidaemia: past evidence and future advances","volume":"8","author":"Ito MK","year":"2002","unstructured":"Ito MK. Niacin-based therapy for dyslipidaemia: past evidence and future advances. Am J Manag Care 2002;8:S315\u2013S322","journal-title":"Am J Manag Care"},{"key":"e_1_2_1_116_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-999-0030-z"},{"key":"e_1_2_1_117_1","doi-asserted-by":"publisher","DOI":"10.1159\/000174681"},{"key":"e_1_2_1_118_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10315"},{"key":"e_1_2_1_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-351X(95)80177-4"},{"key":"e_1_2_1_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/59.10.932"},{"key":"e_1_2_1_121_1","doi-asserted-by":"publisher","DOI":"10.1097\/00132580-200101000-00009"},{"key":"e_1_2_1_122_1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1742-1241.2001.tb11168.x","article-title":"Cholesterol absorption inhibition: a strategy for cholesterol lowering therapy","volume":"55","author":"Miettinen TA","year":"2001","unstructured":"Miettinen TA. Cholesterol absorption inhibition: a strategy for cholesterol lowering therapy. Int J Clin Pract 2001;55:710\u201316","journal-title":"Int J Clin Pract"},{"key":"e_1_2_1_123_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01633.x"},{"key":"e_1_2_1_124_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000018744.58460.62"},{"key":"e_1_2_1_125_1","doi-asserted-by":"publisher","DOI":"10.1136\/heart.85.5.544"},{"key":"e_1_2_1_126_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc4901.100384"},{"key":"e_1_2_1_127_1","first-page":"993","volume":"162","author":"Karen-Morag N","year":"2002","unstructured":"Karen-Morag N, Tanne D, Graff E, Goldbourt U. Low and high density lipoprotein cholesterol and ischemic cerebrovascular disease: the Bezafibrate Infarction Prevention registry. Arch Intern Med 2002;162:993\u20139","journal-title":"U. Low and high density lipoprotein cholesterol and ischemic cerebrovascular disease: the Bezafibrate Infarction Prevention registry. Arch Intern Med"},{"key":"e_1_2_1_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(01)00383-2"},{"key":"e_1_2_1_129_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.13.1711"},{"key":"e_1_2_1_130_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000787"},{"key":"e_1_2_1_131_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000778"},{"key":"e_1_2_1_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(01)00625-8"},{"key":"e_1_2_1_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001483"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079903125001668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:39:48Z","timestamp":1770899988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079903125001668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1185\/030079903125001668"],"URL":"https:\/\/doi.org\/10.1185\/030079903125001668","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}